🟢 Neurosense Therapeutics is trading 9.56% up today after HC Wainwright initiated Buy-rated coverage

Neurosense Therapeutics is trading 9.56% up now at $0.44 after HC Wainwright initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price target.

• The analyst action followed the company’s August 31 announcement of a redesigned, capital-efficient PrimeC development strategy.
• Major U.S. indices were mixed on September 4, 2026, suggesting the move appears company-specific rather than market-driven.